Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06342180
Status:
COMPLETED
Last Update Posted:
2024-04-02
First Post:
2024-03-26
Brief Title:
Metabolic Differences Between Subtypes of Polycystic Ovary Syndrome
Sponsor:
Uşak University
Organization:
Uşak University
Study Overview
Official Title:
Serum Uric Acid Levels in Polycystic Ovary Syndrome Subtypes
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We aimed to investigate serum uric acid levels in patients with different phenotype of policystic ovary syndrome and to compare healthy controls
Detailed Description:
The final breakdown product of adenosine and guanosine-based purines formed as a result of the breakdown of nucleic acids is uric acid UA Uric acid has many beneficial and harmful properties for humans One of the most important benefits of uric acid is that it can act as an antioxidant and is perhaps one of the most important antioxidants in plasma However this hypothesis is completely opposite to the hypothesis advocating an increase in the incidence of hyperuricemia and cardiovascular events There are also experimental studies showing that UA which has an antioxidant effect in the extracellular fluid has harmful effects when it enters the cell Uric acid can contribute to molecular endothelial dysfunction oxidative stress and the formation of many oxygen radicals disruption of the vasodilation mechanism and increased inflammation A correlation has been found between insulin resistance and serum UA level in patients with metabolic syndrome It has been reported in some studies that hyperuricemia can be considered as an indicator of insulin resistance in these patients At the same time many studies have reported that both insulin resistance and hyperuricemia increase cardiovascular risk In a study it was stated that every 1 mgdL increase in serum UA level in women increased the risk of ischemic heart disease by 12
Polycystic ovary syndrome PCOS is one of the endocrinological diseases that affects 5-20 of women of reproductive age It is characterized by oligoanovulation clinical or biochemical hyperandrogenemia and the appearance of polycystic ovaries This syndrome is diagnosed according to the revised 2003 Rotterdan criteria These criteria 1 Oligo-anovulation 2 Clinical andor biochemical hyperandrogenism findings 3 Polycystic ovary PCO appearance in the ovaries For diagnosis it is sufficient to have two of these criteria and not have another disease that causes this
Polycystic ovary syndrome Metabolic disorders such as insulin resistance dyslipidemia glucose intolerance hypertension and obesity are often accompanied and increased inflammation is one of the main characteristics of this syndrome While the presence or absence of PCOS was important until recently recent studies have shown that metabolic changes and inflammation occur at different degrees in different subtypes of PCOS Therefore PCOS cases are divided into 4 subtypes These Subtype 1 has hyperandrogenemia oligoanovulation PCO appearance on ultrasonography USG Subtype 2 has hyperandrogenemia oligoanovulation Subtype 3 has hyperandrogenemia PCO appearance on USG and Subtype 4 has oligoanovulation PCO appearance on USG As the subtype number of polycystic ovary syndrome decreases the severity and frequency of metabolic disorders and inflammation accompanying polycystic ovary syndrome increase
Hyperuricemia is one of the common metabolic disorders in patients with PCOS Prevalence studies have shown that the frequency of hyperuricemia in patients with PCOS is approximately 25 3 times higher than in controls However these studies were conducted in the general PCOS patient group and patients with different subtypes were not evaluated
Since there are different metabolic effects in different subtypes of polycystic ovary syndrome In this study we aimed to investigate whether there is a difference between serum UA levels in different PCOS subtypes Studies investigating UA levels in subtypes of PCOS are rare in the literature We aim to contribute to the knowledge in this field with the results we obtained from this study
Polycystic ovary syndrome PCOS is one of the endocrinological diseases that affects 5-20 of women of reproductive age It is characterized by oligoanovulation clinical or biochemical hyperandrogenemia and the appearance of polycystic ovaries This syndrome is diagnosed according to the revised 2003 Rotterdan criteria These criteria 1 Oligo-anovulation 2 Clinical andor biochemical hyperandrogenism findings 3 Polycystic ovary PCO appearance in the ovaries For diagnosis it is sufficient to have two of these criteria and not have another disease that causes this
Polycystic ovary syndrome Metabolic disorders such as insulin resistance dyslipidemia glucose intolerance hypertension and obesity are often accompanied and increased inflammation is one of the main characteristics of this syndrome While the presence or absence of PCOS was important until recently recent studies have shown that metabolic changes and inflammation occur at different degrees in different subtypes of PCOS Therefore PCOS cases are divided into 4 subtypes These Subtype 1 has hyperandrogenemia oligoanovulation PCO appearance on ultrasonography USG Subtype 2 has hyperandrogenemia oligoanovulation Subtype 3 has hyperandrogenemia PCO appearance on USG and Subtype 4 has oligoanovulation PCO appearance on USG As the subtype number of polycystic ovary syndrome decreases the severity and frequency of metabolic disorders and inflammation accompanying polycystic ovary syndrome increase
Hyperuricemia is one of the common metabolic disorders in patients with PCOS Prevalence studies have shown that the frequency of hyperuricemia in patients with PCOS is approximately 25 3 times higher than in controls However these studies were conducted in the general PCOS patient group and patients with different subtypes were not evaluated
Since there are different metabolic effects in different subtypes of polycystic ovary syndrome In this study we aimed to investigate whether there is a difference between serum UA levels in different PCOS subtypes Studies investigating UA levels in subtypes of PCOS are rare in the literature We aim to contribute to the knowledge in this field with the results we obtained from this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None